Larsucosterol
Larsucosterol (DUR-928), a cholesterol metabolite, is a potent liver X receptor (LXR) antagonist. Larsucosterol as a potent endogenous regulator decreases lipogenesis. Larsucosterol inhibits the cholesterol biosynthesis via decreasing mRNA levels and inhibiting the activation of SREBP-1.
At equivalent molar concentrations, both the salt and free forms of a compound exhibit comparable biological activity. Nevertheless, the salt form (Larsucosterol trimethylamine) usually boasts enhanced water solubility and stability.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 884905-07-1
- Formule: C27H46O5S
- Masse moléculaire:482.72
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Voir tous les produits spécifiques à Isoform Endogenous Metabolite
More
Activité biologique
Description
In Vitro
Larsucosterol (DUR-928; 0-25 μM; 8 h; HepG2 cells) inhibits cholesterol biosynthesis by decreasing HMG-CoA reductase mRNA levels and decreases free [14C] cholesterol in a dose-dependent manner[1].
Larsucosterol (0-25 μM; 6 h; HepG2 cells) inhibits HMG-CoA reductase expression by inhibition of both SREBP1 activation and expression in hepatocytes[1].
Larsucosterol (0-50 μM; 48 h) increases cell proliferation and decreases apoptosis in macrophages[2].
Larsucosterol (0-25 μM; 48 h; macrophages) inhibits activation of liver oxysterol receptor LXRα[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Macrophages
-
Concentration:0, 5, 10, 15, 20, and 25 μM
-
Incubation Time:48 hours
-
Result:Induces cell proliferation and relative cell number after treatment for 48 h were 120% at 25 μM.
-
Cell Line:Macrophages
-
Concentration:0, 5, 10, 15, 20, and 25 μM
-
Incubation Time:48 hours
-
Result:Did not significantly affect the numbers of apoptotic or live cells.
-
Cell Line:HepG2 cells
-
Concentration:0, 3, 6, 12, and 25 μM
-
Incubation Time:6 hours
-
Result:Inhibited the activation of SREBP-1 and SREBP-2, and subsequently inhibit the expression HMG-CoA reductase.
-
Cell Line:Macrophages
-
Concentration:0, 3, 6, 12, and 25 μM
-
Incubation Time:48 hours
-
Result:Decreased LXRα levels in the nuclei in a does-dependent manner.
In Vivo
Larsucosterol (25 mg/kg; i.p.; twice in 14 hours; C57BL/6J mice with nonalcoholic fatty liver diseases (NAFLD) model) suppressed the expression of the genes and inhibits ABCA1 expressionde. Larsucosterolcreases nuclear SREBP-1 Protein levels and cytoplasmic FAS and ACC1 protein levels in liver tissue[3].
Larsucosterol (25 mg/kg; i.p.; once every 3 days for 6 weeks; C57BL/6J mice with nonalcoholic fatty liver diseases (NAFLD) model) protects the liver from injury by suppressing hepatic inflammation[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female C57BL/6J mice with nonalcoholic fatty liver diseases (NAFLD) model[3]
-
Dosage:25 mg/kg
-
Administration:Intraperitoneal injection; once every 3 days for 6 weeks
-
Result:Decreased plasma cholesterol levels.
Reduced serum alkaline phosphatase, ALT, and AST levels.
-
Animal Model:Female C57BL/6J mice with nonalcoholic fatty liver diseases (NAFLD) model[3]
-
Dosage:25 mg/kg
-
Administration:Intraperitoneal injection; twice in 14 hours
-
Result:Decreased plasma TG, CHOL, and HDL-C by 40, 15, and 20%, respectively.
Reduced the mRNA levels of SREBP-1c, ACC1, and FAS by 46, 57, and 49%, respectively.
Suppressed ABCA1 expression.
Suppressed nuclear SREBP-1, cytoplasmic ACC1, and FAS protein levels by 74, 58, and 47%, respectively.
Chemical Information
-
CAS No. 884905-07-1
-
Masse moléculaire 482.72
-
Formule C27H46O5S
-
SMILES
C[C@@]12[C@](CC[C@]2([H])[C@H](C)CCCC(C)(O)C)([H])[C@@]3([H])[C@@](CC1)([H])[C@@]4(C(C[C@H](CC4)OS(=O)(O)=O)=CC3)C
-
Synonyms
DUR-928
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. Ren S, et, al. Sulfated oxysterol, 25HC3S, is a potent regulator of lipid metabolism in human hepatocytes. Biochem Biophys Res Commun. 2007 Sep 7;360(4):802-8. [Content Brief]
[2]. Ma Y, et, al. 25-Hydroxycholesterol-3-sulfate regulates macrophage lipid metabolism via the LXR/SREBP-1 signaling pathway. Am J Physiol Endocrinol Metab. 2008 Dec;295(6):E1369-79. [Content Brief]
[3]. Xu L, et, al. 5-cholesten-3β,25-diol 3-sulfate decreases lipid accumulation in diet-induced nonalcoholic fatty liver disease mouse model. Mol Pharmacol. 2013 Mar;83(3):648-58. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)